Seminars in Oncology
Volume 35, Issue 1 , Pages 72-77 , February 2008

Surgical Management of Inflammatory Breast Cancer

  • S. Eva Singletary

      Affiliations

    • Corresponding Author InformationAddress correspondence to S. Eva Singletary, MD, FACS, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030-4095.

References 

  1. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005-06;22:67–73
  2. Haagensen CD, Stout AP. Carcinoma of the breast (III. Results of treatment, 1935-1942). Ann Surg. 1951;134:151–170
  3. Barber KW, Dockerty MB, Clagett OT. Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1961;112:406–410
  4. Bozzetti F, Saccozzi R, De Lena M, et al. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18:355–361
  5. Chambler AF, Drew P, Hill AD, et al. Inflammatory breast carcinoma. Surg Oncol. 1995;4:245–254
  6. De Lena M, Zucali R, Viganotti G, et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1:53–59
  7. Krutchik AN, Buzdar AU, Blumenschein GR, et al. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979;11:325–332
  8. Pouillart P, Palangie T, Jouve M, et al. Inflammatory breast carcinoma treated with a combination of chemotherapy and radiation therapy (Results of a randomized trial studying the therapeutic role of an immunotherapy with BCG). Bull Cancer. 1981;68:171–186
  9. Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986;4:1765–1771
  10. Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach—M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990;27:94–100
  11. Chevalier B, Bastit P, Graic Y, et al. The Centre H (Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients). Br J Cancer. 1993;67:594–601
  12. Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994;30A:921–927
  13. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994;74(Suppl):466–476
  14. Pawlicki M, Skilyszewski J, Brandys A. Results of combined treatment of patients with locally advanced breast cancer. Tumori. 1983;69:249–253
  15. Brun B, Otmezguine Y, Feuilhade F, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988;61:1096–1103
  16. Fields JN, Perez CA, Kuske RR, et al. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 1989;17:149–155
  17. Thoms WW, McNeese MD, Fletcher GH, et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739–745
  18. Mailosel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990;65:851–855
  19. Pisanski TM, Schaid DJ, Loprinzi CL, et al. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol. 1992;15:376–387
  20. Fein DA, Mendenhall NP, March RD, et al. Results of multimodality therapy for inflammatory breast cancer: an analysis of clinical and treatment factors affecting outcome. Am Surg. 1994;60:220–225
  21. Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide in a combined modality approach for locally advanced and inflammatory breast cancer. Am J Clin Oncol. 1996;19:10–17
  22. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–1208
  23. Arthur DW, Schmidt-Ullrich RK, Friedman RG, et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 1999;44:289–296
  24. De Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery?. Ann Oncol. 2000;11:1147–1153
  25. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987;47:3889–3894
  26. Hortobagyi G, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In:  Harris JR,  Lippman ME,  Morrow M editor. Treatment of locally advanced and inflammatory breast cancer. Philadelphia: Lippincott, Williams & Wilkins; 2000;p. 645–660
  27. Vlastos G, Fornage BD, Mirza NW, et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg. 2000;179:446–452
  28. Fleming RYD, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452–461
  29. Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer—a reassessment of margin status. Ann Surg Oncol. 1999;6:249–254
  30. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Nat Cancer Inst. 2005;97:966–975
  31. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–2702
  32. Stearns V, Ewing A, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9:235–242
  33. Davis JT, Brill YM, Simmons S, et al. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. Ann Surg Oncol. 2006;13:1545–1552
  34. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62:2507–2516
  35. Hunt KK, Baldwin BJ, Strom EA, et al. Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction. Ann Surg Oncol. 1997;4:377–384
  36. Williams JK, Carlson GW, Bostwick J, et al. The effects of radiation treatment after TRAM flap breast reconstruction. Plast Reconstr Surg. 1997;100:1153–1160
  37. Evans GR, Schusterman MA, Kroll SS, et al. Reconstruction and the radiated breast: is there a role for implants?. Plast Reconstr Surg. 1995;96:1111–1115
  38. Chin PL, Anderson JS, Somlo G, et al. Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile?. J Am Coll Surg. 2000;190:304–309
  39. Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg. 1994;93:1191–1204

PII: S0093-7754(07)00233-3

doi: 10.1053/j.seminoncol.2007.11.008

Seminars in Oncology
Volume 35, Issue 1 , Pages 72-77 , February 2008

Article Tools

* Image Usage & Resolution